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Protection of epithelial barrier function by the Crohn's disease
associated gene protein tyrosine phosphatase n2
Abstract
BACKGROUND & AIMS: Protein tyrosine phosphatase N2 (PTPN2) has been identified as a Crohn's
disease (CD) candidate gene. However, a role for PTPN2 in the pathogenesis of CD has not been
identified. Increased permeability of the intestinal epithelium is believed to contribute prominently to
CD. The aim of this study was to determine a possible role for PTPN2 in CD pathogenesis. METHODS:
Intestinal epithelial cell (IEC) lines T(84) and HT29cl.19a were used in all studies. Protein analysis was
performed by Western blotting, and protein knockdown was induced by small interfering RNA. Primary
samples were from control and CD patients. RESULTS: Here, we demonstrate increased PTPN2
expression in CD intestinal biopsy specimens and that the proinflammatory cytokine interferon
(IFN)-gamma increases PTPN2 expression and activity in IEC. Moreover, IFN-gamma-induced STAT1
and STAT3 phosphorylation in IEC is enhanced by PTPN2 knockdown. The cellular energy sensor
adenosine monophosphate-activated protein kinase partially regulates the IFN-gamma-induced effects
on PTPN2. Additionally, PTPN2 knockdown potentiates IFN-gamma-induced increases in epithelial
permeability, accompanied by elevated expression of the pore-forming protein claudin-2.
CONCLUSIONS: PTPN2 is activated by IFN-gamma and limits IFN-gamma-induced signalling and
consequent barrier defects. These data suggest a functional role for PTPN2 in maintaining the intestinal
epithelial barrier and in the pathophysiology of CD.
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Abstract 
Background & Aims: Protein tyrosine phosphatase N2 (PTPN2) has been identified as a 
Crohn’s disease (CD) candidate gene. However, a role for PTPN2 in the pathogenesis of CD has 
not been identified. Increased permeability of the intestinal epithelium is believed to contribute 
prominently to CD. The aim of this study was to determine a possible role for PTPN2 in CD 
pathogenesis. Methods: Intestinal epithelial cell (IEC) lines, T84 and HT29cl.19a, were used in 
all studies. Protein analysis was by Western blotting and protein knock-down by siRNA. Primary 
samples were from control and CD patients. Results: Here, we demonstrate increased PTPN2 
expression in CD terminal ileum and colonic biopsies and the pro-inflammatory cytokine, IFN, 
increases PTPN2 expression and activity in IEC. Moreover, IFN-induced STAT1 and STAT3 
phosphorylation in IEC is enhanced by PTPN2 knock-down. The cellular energy sensor, AMPK, 
partially regulates the IFN-induced effects on PTPN2. Additionally, PTPN2 knock-down 
potentiates IFN-induced increases in epithelial permeability, accompanied by elevated 
expression of the pore-forming protein, claudin-2. Conclusions: In summary, PTPN2 is activated 
by IFN and limits IFN-induced signalling and consequent barrier defects. These data suggest a 
functional role for PTPN2 in maintaining the intestinal epithelial barrier and in the 
pathophysiology of CD.       
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Introduction 
The family of protein tyrosine phosphatases (PTPs) plays a critical role in regulating fundamental 
cellular signalling events, including cell proliferation, differentiation and survival1. A single 
nucleotide polymorphism (SNP) in the gene locus encoding one such phosphatase, protein 
tyrosine phosphatase N2 (PTPN2), has been associated with Crohn’s Disease (CD), Type I 
diabetes, and ulcerative colitis (UC)2-6. However, a functional role for PTPN2 in the pathogenesis 
of CD has not been identified. PTPN2, also referred to as T-cell protein tyrosine phosphatase 
(TC-PTP), exists in two different splice forms, a nuclear 45kD and a cytoplasmic 48kD variant 
that is bound to the endoplasmic reticulum. Upon activation, the nuclear variant, which seems to 
be more important for PTPN2 catalytic activity7-11, can exit the nucleus12. In fibroblasts, this 
event is dependent upon activation of the cellular energy sensor, adenosine monophosphate-
activated protein kinase (AMPK)8. Among the PTPN2 substrates are receptors for epidermal 
growth factor9, 10, and insulin13 and the Signal transducers and activators of transcription (STAT) 
1+37, 11, 14.  
 
Inflammatory bowel disease (IBD) is comprised of CD and UC. Genetic, immunological and 
bacterial factors are involved in IBD pathogenesis. Evidence suggests that an epithelial barrier 
defect, coupled with a dysfunctional immune response to commensal flora, drives the 
development of chronic intestinal inflammation15. Both IBD subgroups are characterized by their 
specific cytokine profile, with elevated levels of interferon gamma (IFN) predominating in 
CD16. The most important mediators of IFN-induced signalling are the STATs17, with 
upregulation of both STAT1+3 observed in IBD18,19. In addition to a possible role in the onset of 
CD, increased epithelial barrier permeability may also contribute to the major clinical symptom 
of CD, diarrhea, due to “leak-flux” of electrolytes and water into the lumen. In cell culture 
studies, IFN reduces intestinal epithelial barrier function. Recent publications demonstrated 
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upregulation of the pore forming claudin-2 in colonic crypt epithelial cells in CD20, 21. Moreover, 
increased claudin-2 levels correlate with increased permeability20, 22-24.  
 
We found that PTPN2 is upregulated both in IECs following IFN treatment and in CD 
patient biopsies, and this effect in IECs is, at least in part, AMPK-dependent. We show that 
PTPN2 knock-down leads to elevated claudin-2 expression, correlating with a further increase in 
IFN-induced epithelial permeability. These data establish PTPN2 as a protective factor in a cell 
model of chronic intestinal inflammation and implicate PTPN2 dysfunction in CD pathogenesis. 
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Methods  
Materials 
Human recombinant IFN (Roche, Mannheim, Germany), Compound C (CC), AICA-Riboside-
5’-phosphate (AICAR), and monoclonal mouse anti-PTPN2 antibody CF-4, which detects the 
45kD and the 48kD isoforms (Calbiochem San Diego, CA), rabbit anti-lamin A/C (Santa Cruz 
Biotechnology, Santa Cruz, CA), mouse anti-claudin-2, anti-claudin-4, anti-ZO-1 and rabbit anti-
occludin antibodies (Zymed Laboratories, Carlsbad, CA) were obtained from the sources noted. 
Rabbit anti-phospho-AMPKThr172), anti-AMPK, anti-phospho-STAT1 (Tyr701), anti-
STAT1, anti-phospho-STAT3 (Tyr705) and anti-STAT3 antibodies were obtained from Cell 
Signaling Technologies (Danvers, MA). All other reagents were of analytical grade and acquired 
commercially.  
 
Cell culture 
Human colonic crypt T84 IEC were cultured as described previously25. Human HT29cl.19a IEC 
were cultured in McCoy’s 5A Medium (JRH, Lenexa, Kansas) supplemented with 10% fetal calf 
serum and separated by trypsinisation. While IFNwas added basolaterally, the AMPK inhibitor, 
CC (50 M), and the AMPK activator, AICAR (1 mM), were added bilaterally. 
 
Patient samples 
Tissue specimens were prospectively collected from the terminal ileum, colon or rectum of male 
and female individuals with and without CD. All patients with active CD (n = 9, age-range 31-75 
years, mean: 55+/-5 years) presented clinically and macroscopically signs of acute inflammation. 
Biopsies were taken from macroscopically inflamed appearing regions. All patients with CD in 
remission (n = 7, age-range 24-74 years, mean: 46+/-8 years) were presenting for surveillance 
colonoscopy and did not show any clinical or macroscopic signs of acute or chronic 
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inflammation. Biopsies were taken from macroscopically uninflamed appearing regions. Control 
patients (n = 9, age-range 30-74, mean: 46+/-4) were asymptomatic and presented for colon 
cancer screening. Biopsy specimen of all of the patients were H&E stained and used for 
microscopic assessment of their inflammatory status. The assessment was performed by a 
professional pathologist (A.W.) in a blinded manner. Patient characteristics are presented in 
Supplementary Table 1. Tissue pieces used for RNA analysis were transferred into RNAlater 
solution (Qiagen, Valencia, CA), immediately frozen and stored at -80°C. Tissue samples used 
for microscopic assessment were immediately transferred into 4 % formalin and stored at 4°C 
until further staining and analysis. Written informed consent was obtained before specimen 
collection and studies were approved by the Cantonal Ethics Committee of the Canton Zurich. 
 
RNA isolation and real-time PCR 
Total RNA was isolated using RNeasy Plus Mini Kit (Qiagen, Valencia, CA) and RNA 
expression was analyzed by real-time PCR. Experimental procedures, real-time PCR conditions 
and primer sequences (Integrated DNA Technologies, Coralville, IA) are described in the 
Supplementary Methods.  
 
Preparation of whole cell lysates 
T84 and HT29cl.19a lysates were prepared as described previously25. The protein content was 
adjusted to ensure the same amount of total protein in each sample. 
 
Preparation of cytoplasmic and nuclear lysates 
Separate cytoplasmic and nuclear lysates were obtained using a Nuclear Extraction Kit (Imgenex, 
San Diego, CA). Briefly, T84 cells were scraped off of filters and cytoplasmic proteins were 
collected using a 1x hypotonic buffer and incubated with a 10% detergent solution. The nuclear 
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fraction was collected using a Nuclear Lysis Buffer. Finally, the protein content was determined 
and adjusted as described above. 
 
Western blotting 
Western analysis of cell lysates was performed as previously25. 
 
Confocal microscopy 
5x105 T84 cells were seeded onto 12-mm Millicell-HA filters for 6 days before stimulation. 
Experimental conditions and staining protocols are described in detail in the Supplementary 
Methods.  
  
Phosphatase activity assay 
Phosphatase activity was assessed using the EnzChek Phosphatase Assay Kit (Molecular Probes) 
according to manufacturer’s instructions and as described in Mattila et al.10. PTPN2 was 
immunoprecipitated from whole cell lysates using anti-PTPN2 antibody (1g/ml; 1h) and 
fluorescence in immunoprecipitates was detected on a SpectraMax M2 Fluorescence Microplate 
reader using SoftMax Pro v5 Software (Molecular Devices, Sunnyvale, CA). Measurements were 
performed in triplicates. Remaining immunoprecipitates were used for Western blotting to ensure 
equal amounts of PTPN2 in each sample. 
 
Small interfering RNA (siRNA) transfection 
T84 (2x106) or HT29cl.19a (1x106) cells were seeded 3 days before transfection. For PTPN2 and 
AMPK1 (PRKAA1) genes, 100 pmol of three different annealed Silencer Pre-designed siRNA 
oligonucleotides (Applied Biosystems; Supplementary Methods) were transfected into T84 or 
HT29cl.19a cells using the Amaxa nucleofector system (Amaxa, Gaithersburg, MD). After 
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transfection, IEC were cultured on filter membranes for 48 h before treatment. Control siRNA 
SMARTpool (Upstate Biotechnology/Dharmacon, Chicago, IL) (100 pmol/transfection) was 
used as negative control. 
 
Transepithelial permeability studies 
Transepithelial permeability was measured as 10 kD fluorescein isothiocyanate-dextran (FITC-
Dextran) (Sigma St. Louis, MO) flux across IEC monolayers. Following IFN treatment, cells 
were washed (x3) and incubated for 30 min at 37°C with Ringer’s to equilibrate. FITC-Dextran 
(1 mg/ml) was added to the apical compartment of the monolayer. 1 h later, 100 l of the 
basolateral solution was removed and fluorescence was detected using a microplate reader 
(Molecular Devices). 
 
Transepithelial electrical resistance (TER) 
TER across T84 monolayers was assessed by voltohmeter (WPI, Sarasota, FL) and companion 
electrodes (Millipore, Bedford, MA). Measurements were calculated in Ω · cm2 and expressed as 
% control. 
 
Statistical analysis 
Data are presented as means +/- S.E.M. for a series of n experiments. Data are expressed as a 
percentage of the respective controls, fluorescence units (Figure 2A) or arbitrary units (Figure 1d, 
Supplementary Figure 3). Statistical analysis was performed by Analysis of Variance (ANOVA) 
and Student-Newman-Keuls post-test or student’s t-test, where appropriate, using Graph Pad 
Instat 3 software (Graph Pad Software, La Jolla, CA). P values < 0.05 were considered 
significant. 
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Results 
IFN increases PTPN2 expression in IEC 
 To investigate if IFN affects epithelial PTPN2 expression, T84 cells were treated with IFN 
(1000 U/ml) for 24, 48 and 72 h. IFN significantly increased PTPN2 mRNA expression (Figure 
1a). Western blot experiments revealed consistently increased levels of cytoplasmic PTPN2 
protein (Figure 1b). However, in the nuclear compartment, a significant increase could only be 
observed in 24 h IFN-treated cells, with diminishing effects thereafter (Figure 1c). Dose-
response studies revealed that a concentration of 1000 U/ml IFN caused a maximal increase in 
PTPN2 protein by 24 h IFN treatment and PTPN2 protein was not further increased by higher 
cytokine concentrations (Supplementary Figure 1). In a previous study26, cultured biopsies from 
patients with active CD have been shown to release IFN at levels as high as approximately 1000 
U/ml/mg tissue, although the mean level was 75 +/- 215 U/ml/mg tissue. Serum levels of IFN in 
these studies were understandably much lower due to dilution of the high local level of IFN 
originating in the intestinal mucosa. Although much of our data was generated using 1000 U/ml 
of IFN, we do show in Supplementary Figure 1 approximately similar effects of 100 vs. 1000 
U/ml of IFN on PTPN2 expression in IEC. Therefore, while 1000 U/ml is at the high end of the 
pathologic range, the experimental use of this concentration is not unreasonable. IFN also 
elevated PTPN2 protein in HT29cl.19a IEC (Supplementary Figure 2a). 
To demonstrate the relevance of our studies to human disease, we investigated PTPN2 
mRNA levels in human biopsy specimens from macroscopically non-inflamed areas of the 
terminal ileum, colon or rectum of CD patients in clinical and macroscopic remission, 
macroscopically inflamed areas of the terminal ileum and colon of CD patients with clinically 
and macroscopic active disease or healthy control subjects undergoing routine colon cancer 
screening. We found that PTPN2 mRNA was significantly elevated in tissue samples of CD 
patients with acute inflammation (p<0.05), but not in CD patients in remission (Figure 1d). 
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Correlating to increased PTPN2 mRNA levels, CD patients with active disease also showed an 
about three-fold increase in IFN mRNA levels compared to healthy controls (Supplementary 
figure 3). However this increase did not reach significance, due to the broad range of IFN levels 
in each of the single samples. In contrast, IFN mRNA levels in CD patients in remission where 
not different from the levels in control patients (Supplementary figure 3). Additionally, 
microscopic assessment of H&E-stained biopsy specimen from the respective patients did not 
show any microscopic signs of inflammation in either control patients or patients with CD in 
remission, but revealed signs of acute inflammation when derived from patients with active CD 
(Supplementary figure 4). These findings are of special interest, since they demonstrate the 
importance of our study to “bona fide” human disease.   
 
 
 
PTPN2 activity is elevated by IFN 
We investigated whether IFN alters PTPN2 enzymatic activity in T84 cells. We found that IFN 
increases PTPN2 activity maximally within 72 h of treatment in PTPN2 immunoprecipitates 
generated from whole cell lysates (Figure 2a). We studied the activation status of the PTPN2 
target proteins, STAT1 and STAT3 by measuring phosphorylation on tyrosine701 and tyrosine705, 
respectively. We hypothesized that increased PTPN2 activity should correlate with decreased 
phosphorylation of STAT1+3. Western blot analysis revealed that IFN treatment for 24 h not 
only enhanced cytoplasmic and nuclear STAT1 phosphorylation (Figure 2b,c), but also increased 
STAT1 expression (Figure 2b,c). In keeping with our hypothesis, however, STAT1 
phosphorylation subsequently declined in both compartments in parallel with increased PTPN2 
activity, albeit with different kinetics. Nuclear STAT1 phosphorylation was no longer 
significantly increased at 48 h IFN treatment and declined to control levels by 72 h. This 
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suggests that PTPN2 activity was capable of significantly dephosphorylating STAT1 already 
between 24 to 48 h after IFN treatment in the nuclear compartment (p<0.001). In contrast, 
cytoplasmic STAT1 phosphorylation, although reduced, was still significantly increased even at 
48 h treatment (p<0.05). Since prior observations in fibroblasts point to the presumption that the 
48kD variant of PTPN2 is less active than the nuclear variant, we speculate that this difference in 
the catalytic activity between both of the PTPN2 isoforms might also be detectable in T84 IEC. 
Therefore, a possible explanation for the observation that cytosolic STAT1 phosphorylation 
already declines after 48 h IFN treatment might be that a small, but sufficient, amount of the 
nuclear PTPN2 variant is already in the cytosolic compartment and/or has already exited the 
nucleus. Additionally, since STAT1 is a transcription factor, it translocates after its activation 
from the cytoplasm into the nucleus, where it becomes dephosphorylated by the nuclear PTPN2 
isoform, and is, subsequently, not detectable in the cytosolic protein fraction anymore. Similar 
data were obtained regarding IFN-induced cytoplasmic STAT3 phosphorylation (Figure 2d). 
      The delay in increased activity of PTPN2 is at odds with increased PTPN2 expression at 24 h. 
A possible explanation for this dichotomy is that whole cell lysates used for the PTPN2 activity 
assay contained only a small portion of the nuclear protein fraction (Supplementary Figure 5).  
It is possible that only low levels of the nuclear 45kD isoform of PTPN2 were present in the 
whole cell lysates at the earlier timepoints of 24 and 48 h, whereas by 72 h, significant levels of 
the 45kD variant had exited the nucleus. Therefore, we speculate that in response to IFN 
treatment a certain amount of the nuclear 45kD PTPN2 variant shifts from the nucleus into the 
cytoplasm. So, a cytoplasmic accumulation of PTPN2 in T84 cells in response to 72 h IFN 
treatment may contribute to STAT1 dephosphorylation in the cytoplasmic cell compartment, as 
well as to the significantly increased PTPN2 activity (Figures 2a-c). 
Though our data suggest that IFN increases PTPN2 activity and this correlates with 
downregulation of IFN-induced STAT signalling in IEC, basal PTPN2 is also likely to be 
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involved in STAT dephosphorylation. Further studies will be needed to investigate the effects of 
IFN on the catalytic activity of the different isoforms of PTPN2 in detail.  
 
Loss of PTPN2 enhances STAT1 and STAT3 phosphorylation 
We next investigated whether knock-down of PTPN2 conversely elevated STAT1+3 activity. T84 
cells were transfected with either PTPN2-specific siRNA or non-specific control siRNA 
sequences and subsequently treated with IFN (24 h). PTPN2 siRNA decreased PTPN2 
expression with a maximal reduction of 92 ± 3% (Figure 3a). Non-specific effects on protein 
levels were not observed, as shown by equivalent levels of the nuclear envelope protein lamin 
A/C and total STAT1+3 in both subgroups (Figure 3a-c). As expected, IFN increased PTPN2 
protein (Figure 3a) as well as STAT1+3 phosphorylation (Figure 3b,c). PTPN2 knock-down 
amplified STAT1+3 phosphorylation (Figure 3b,c). Similar findings were observed in separately 
collected cytoplasmic and nuclear protein fractions of 24 h IFN-treated T84 monolayers (Figure 
3d). siRNA-induced knock-down of PTPN2 in HT29cl.19a cells revealed the same regulatory 
influence of PTPN2 on STAT1 phosphorylation (Supplementary Figure 2a,b). These data, in 
addition with those in Figure 2a-d, indicate that PTPN2 is the cellular phosphatase of STAT1+3 
in IEC, and that PTPN2 terminates IFN-induced STAT signalling. 
 
 
 
IFN regulates PTPN2 activation via AMPK 
The cellular energy sensor, AMPK, has been shown in fibroblasts to participate in regulation of 
PTPN2 nuclear-cytoplasmic shuttling. Therefore, we investigated if AMPK modified the effects 
of IFN on PTPN2 expression, activity and subcellular distribution in IECs. AMPK activity was 
assessed by phosphorylation of Thr172 on the AMPK catalytic 1-subunit in T84 cells. Western 
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blot analysis revealed that IFN induced AMPK activation in a time-dependent manner, reaching 
a peak at 6 h (Figure 4a). This effect was sensitive to the AMPK inhibitor, compound C (CC; 50 
M), which competes for binding of intracellular ATP to AMPK and inhibits its phosphorylation 
by upstream kinases. CC co-treatment significantly inhibited IFN-induced AMPK 
phosphorylation (Figure 4b). To determine if AMPK is involved in the regulation of PTPN2 
protein, we stimulated T84 monolayers with IFN and/or CC for 72 h. IFN treatment increased 
cytoplasmic and nuclear PTPN2 levels, an effect that was partially diminished in the presence of 
CC. Thus, AMPK mediates, at least in part, IFN-induced PTPN2 expression although additional 
pathways may also be involved (Figure 4c,d). 
Since we have shown that STAT1 phosphorylation kinetics can be used as a marker of 
PTPN2 activity, we surmised that STAT1 phosphorylation in cells treated with IFN and CC 
should be higher than in cells treated with IFN alone. Indeed, while IFN treatment (72 h) 
increased cytoplasmic and nuclear STAT1 phosphorylation (Figure 4e,f), co-treatment with CC 
potentiated cytoplasmic (Figure 4e), and nuclear (Figure 4f) STAT1 activity above that induced 
by IFN alone. Interestingly, CC alone had no effect on STAT1 phosphorylation. In contrast, 
AMPK activity alone, as induced by the pharmacological activator AICAR (1 mM), neither 
induced PTPN2 expression nor altered STAT1 phosphorylation (Supplementary Figure 6). These 
data indicate that the role of AMPK in modifying cellular PTPN2 protein levels and downstream 
STAT1 dephosphorylation is dependent not only on IFN-stimulated AMPK activity, but also on 
other aspects of the signalling milieu existing in IFN- vs. AICAR-treated cells. Therefore, 
further studies will be required to determine additional pathways that are likely involved in the 
regulation of IFN-induced effects on PTPN2 besides AMPK. 
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AMPK regulates IFN-induced PTPN2 cytoplasmic accumulation 
Maximal IFN-induced PTPN2 activity is detectable by 72 h. However, the peak of IFN-
induced AMPK phosphorylation was seen by 6 h. We hypothesized that the 45kD PTPN2 
isoform, which likely accounts for the majority of PTPN2 activity, shifts from the nucleus to the 
cytoplasm in response to IFN. Therefore, we examined if IFN affects the cellular distribution 
of PTPN2. In untreated T84 cells, PTPN2 was evident in the cytoplasm and the nucleus (Figure 
5a). A similar pattern of PTPN2 distribution was observed in 24 h IFN-treated cells 
(Supplementary Figure 7). This finding supports our Western blot data (Figure 1c) and our 
hypothesis that nuclear PTPN2 protein is highest from 0-24 h after IFN treatment. Therefore, we 
think that 24 h treatment with IFN increases PTPN2 protein in both cell compartments 
independently of possible alterations in the cellular distribution of PTPN2.  
In contrast, in 72 h IFN-treated monolayers PTPN2 protein was more prominent in the 
cytoplasm than the nucleus compared to untreated control cells (Figure 5a). These findings 
further support our hypothesis, as well as our previous PTPN2 data (Figures 1b,2a), suggesting 
that the majority of the nuclear 45kD variant of PTPN2 shifts from the nucleus to the cytoplasm 
in response to 72 h IFNtreatment and accounts for the significant increase in PTPN2 activity at 
this timepoint. We further investigated whether AMPK inhibition by CC modulates PTPN2 
distribution. In T84 monolayers treated with CC alone, PTPN2 was equally distributed in 
cytoplasmic and nuclear compartments as seen in untreated control cells. However, CC co-
treatment clearly attenuated the IFN-induced cytoplasmic accumulation of PTPN2. Though 
PTPN2 was still prominent in the cytoplasm of co-treated cells, PTPN2 was more visible in the 
nucleus in comparison to IFN treatment alone (Figure 5a). Though these data indicate that the 
extra-nuclear localization of PTPN2 in response to IFN is, at least in part, AMPK-dependent, 
although additional pathways are likely involved. 
 
 15
 AMPK knock-down attenuates IFN-induced increases in PTPN2 expression 
To confirm the regulatory effect of AMPK on PTPN2 we transfected T84 cells with either control 
or AMPK-1 targeting siRNAs. In cells transfected with AMPK siRNA, AMPK was 
significantly lowered by 64 ± 11% (Figure 5b), while lamin A/C and total STAT1 were not 
affected (Figure 5b-d). IFN treatment (24 h) increased PTPN2 expression and STAT1 
phosphorylation in control siRNA-transfected cells (Figure 5c,d). However, AMPK-deficient 
cells showed, in parallel with decreased PTPN2 expression, a potentiation of IFN-induced 
STAT1 phosphorylation (Figure 5c,d). These data confirm that AMPK activity plays a partial but 
important role in regulating PTPN2 expression and activity in response to IFN in IEC. 
 
 
 
PTPN2 knock-down increases epithelial permeability  
We next determined whether PTPN2 mediates the IFN-induced decrease in barrier function. We 
assessed epithelial permeability by measuring flux of 10kD FITC-Dextran across T84 and 
HT29cl.19a monolayers, transfected with either control or PTPN2-specific siRNA and 
subsequently treated with IFN (72 h). PTPN2 siRNA significantly decreased PTPN2 expression 
(Figure 6a; Supplementary Figure 2a). As expected, IFNsignificantly increased permeability in 
cells transfected with non-specific siRNA. However, PTPN2 knock-down further exacerbated 
barrier dysfunction following IFN treatment in both IEC lines (Figure 6a, Supplementary Figure 
2c). Additionally, loss of PTPN2 further aggravated the IFN-induced decrease in TER across 
T84 monolayers (Figure 6b). These data suggest that PTPN2 plays an important role in stabilizing 
intestinal epithelial barrier function during exposure to inflammatory cytokines.  
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The pore-forming protein, claudin-2, plays an important role in regulating epithelial 
permeability in CD and UC20, 21, 23. In T84 cells transfected with control siRNA, IFN treatment 
did not affect claudin-2 expression. However, in parallel with the rise in epithelial permeability, 
IFN significantly increased expression of claudin-2 in PTPN2-deficient cells (Figure 6c). In 
contrast, while the expression of ZO-1 and occludin was reduced by IFN, this was not further 
affected by PTPN2 knock-down. Moreover, claudin-4 levels remained stable under all conditions 
(Figure 6d). Overall, our data indicate that a lack of PTPN2 enables IFN-stimulated expression 
of claudin-2, which is believed to contribute to increased permeability in IBD. These data thus 
illustrate a novel role for PTPN2 in protecting epithelial barrier function.  
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Discussion 
PTPN2 plays a critical role in regulating cytokine signalling in immune cells by inactivating 
STAT1+37, 11, 14. These findings are supported by observations in PTPN2-/- mice that die within 
3-5 weeks from progressive systemic inflammation accompanied by elevated serum levels of 
IFNand TNF. We demonstrated that IFN increases PTPN2 expression and activity in IEC. 
Activated PTPN2, in turn, reduces IFN-induced STAT1+3 activation. These data were 
corroborated by PTPN2 knock-down studies. We can speculate that PTPN2 participates in a 
negative feedback mechanism activated by IFN and thus limits cytokine signalling. STAT1+3 
affect different target genes and induce different biological effects. STAT1 plays a decisive role 
in mediating IFN-dependent immunomodulatory, antiproliferative and antiviral effects17. In 
contrast, STAT3 has primarily oncogenic as well as anti-apoptotic effects28 and plays an 
important role in the pathogenesis of colon cancer, which has a higher frequency in IBD 
patients29. Overall, strict regulation of STAT1+3 signalling is crucial for intestinal homeostasis. 
Our data establish PTPN2 as a key regulator of STAT1+3 phosphorylation and IFN-induced 
signalling in IEC in particular. 
 
We observed that PTPN2 is regulated in T84 cells, at least in part, via IFN-induced AMPK 
activation. In response to reduced cellular energy levels, AMPK limits energy-consuming and 
activates energy-generating processes30. Energy consuming processes in the intestine include ion 
transport and epithelial barrier maintenance. Both of these functions are compromised by 
exposure to IFN25, 31, 32, and in IBD33, 34. AMPK is thus a logical mediator of IFN signalling. 
However, AMPK activity alone was unable to affect PTPN2 expression. Therefore, accessory 
signals that are activated by IFN, in addition to AMPK, may also play an important role in the 
regulation of PTPN2. Identification of these signals was beyond the scope of the present study. 
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Nevertheless, our data indicate that AMPK is necessary, though not sufficient, to mediate 
important downstream effects of IFN relevant to intestinal inflammation. 
 
The ability of IFN to increase epithelial permeability and decrease TER was significantly 
enhanced by PTPN2 knock-down and accompanied by increased expression of claudin-2. The 
claudins are a family of tight junction proteins that play a crucial role in regulating paracellular 
permeability22,35. Increased epithelial permeability is believed to contribute substantially to the 
pathophysiology of CD36. Although the claudins function to seal the tight junction, claudin-2 is 
unusual in that it forms a cation-selective membrane pore for substrates smaller than 4 Angstrom 
and may therefore directly account for the further decrease in TER across IFN-treated PTPN2-
deficient T84 monolayers. However, it is not possible that the increased FITC-dextran flux 
observed in our studies occurs via passage through this specific pore. Moreover, increased 
numbers of claudin-2 molecules do not directly correlate with increased permeability for 
substrates that exceed its pore size23. However, claudin-2 is upregulated in intestinal crypt 
epithelium in CD20. Similarly, in active CD, the number of tight junction strand breaks in the 
colonic epithelium is increased. These breaks, of ≥25 nm, mean that even large macromolecules, 
such as the 10kD FITC-dextran used here, can pass through20. Moreover, increased expression of 
claudin-2 correlates with the appearance of discontinuous tight junction strands37. It is plausible 
that the increased FITC-dextran flux observed reflects such discontinuities. Therefore, claudin-2 
itself cannot be responsible for the increased permeability to 10 kD-dextran in our studies, since 
its pore size is obviously too small that macromolecules, such as dextrans, could pass through the 
pore. Nevertheless, we speculate, in good agreement with findings of Zeissig et al.20, that 
increased levels of claudin-2 cause a different composition of the intercellular tight junctions 
resulting in an elevated number of strand breaks and discontinous tight junction strands finally 
resulting in a disturbed tight junction pattern that even allows macromolecules, such as 10 kD-
dextran to pass through. This scenario would fit with other findings showing an essential role for 
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claudin-2 in regulating the structural composition of tight junctions, and consequently in 
modifying epithelial permeability20-24, 38. 
 
Claudin-2 expression in T84 cells is not increased by IFNalone21, 38. However, when PTPN2 
expression is repressed, IFN can increase claudin-2 expression and further elevate epithelial 
permeability. These findings imply that PTPN2 normally prevents a rise in claudin-2 expression 
in response to IFN. Moreover, the IFN-induced elevation of claudin-2 expression in PTPN2-
deficient cells may be mediated by STAT proteins as we have identified a putative 
STAT1/STAT3 binding sequence in the claudin-2 promoter region39, 40, which is likely needed 
for STATs to have a regulatory effect on claudin-2 expression. Since, to the best of our 
knowledge, no STAT binding motif has been described within the claudin-2 promoter, we 
screened the claudin-2 promoter region39 for such a motif. All STATs recognize the same 
palindromic sequence, TTCNNNGAA (where N is a variable spacer). By blast search, we 
identified such a palindromic motif 260 to 252bp upstream in the claudin-2 promoter 
(Supplementary Figure 8). The identified sequence, 5’-TTCCCGGAA-3’ matches the criteria for 
a possible STAT1 binding motif40 and matches exactly with the STAT3 binding motif in the gene 
encoding human p21WAF40. Thus, we present a plausible candidate sequence for STAT-
dependent regulation of claudin-2 expression. Though the nature of STAT regulation of claudin-
2 expression, and the interaction with the putative STAT binding motif need to be investigated in 
the future, these findings support our hypothesis that PTPN2 knock-down leads to increased 
claudin-2 expression in response to IFN, possibly via upregulation of STAT1 and/or STAT3.   
  
Whether PTPN2 restricts the interaction of STAT proteins with various promoters, perhaps 
by reducing their phosphorylation, remains to be elucidated. In any event, our findings indicate 
that PTPN2 may protect epithelial barrier function during exposure to inflammatory cytokines. 
Conversely, dysfunction of PTPN2 could play an important role in the pathogenesis of CD, a 
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chronic inflammatory disease featuring elevated levels of IFN. A mutation in the PTPN2 gene 
locus has been associated with CD3, 5, 6 and it is possible that this mutation could lead to a loss of 
functional PTPN2 in this disease (although this has not been formally demonstrated and, to the 
best of our knowledge, functional consequences of the specific PTPN2 SNP have not been 
reported) and to the downstream consequences described herein. Future studies should identify 
whether loss of functional PTPN2 might permit passage of large molecules that might initiate or 
exacerbate episodes of intestinal inflammation, across the intestinal epithelium. We also 
observed increased PTPN2 expression in biopsies from CD patients featuring active 
inflammation vs. normal subjects, which is in line with our in vitro data showing that IFN 
increases PTPN2 expression. These data provide proof of principle of altered PTPN2 expression 
in CD. However, a more detailed study will be required to determine whether there are differing 
levels of activity of PTPN2 in active and inactive CD tissues. A similar analysis will need to be 
performed in tissues from patients harbouring the PTPN2 SNP for comparison. 
 
In summary, our data show that loss of PTPN2 function leads not only to a prolonged and 
more severe inflammatory signalling cascade in response to IFN, but critically to a defect in 
epithelial barrier function. Taken together, these findings suggest that PTPN2 activity is crucial 
for regulating inflammatory processes and preserving intestinal epithelial barrier function in the 
setting of inflammation. These data indicate a mechanistic role for PTPN2 in restricting the 
pathogenesis of CD and provide a functional basis for the identification of PTPN2 as a CD 
candidate gene. 
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Figure legends 
 
Figure 1. IFNincreases PTPN2 levels in T84 cells and human colonic biopsy specimens.  (a) 
PTPN2 mRNA expression in response to IFN, normalized to GAPDH (n=3, performed in 
triplicate). (b) Cytoplasmic PTPN2 protein in IFN-treated T84 cells shown by representative 
Western blots. Lamin A/C was used throughout as a loading control. The relative protein level 
was assessed by densitometric analysis (n=4). (c) Nuclear PTPN2 protein in IFN-treated T84 
cells is demonstrated by representative Western blots and densitometric analysis (n=4). Data are 
expressed as a percentage of the respective control. (d) PTPN2 mRNA in human terminal ileum 
and colon biopsies from CD patients with active disease (n=9) and in remission (n=7) as well as 
from control subjects (n=9). PTPN2 mRNA expression was normalized to the housekeeping gene 
GAPDH. Measurements were performed in triplicates. Asterisks denote significant differences 
from the respective control (*=p<0.05, **=p<0.01, ***=p<0.001).  
 
 
 
Figure 2. Elevated PTPN2 activity parallels decreased STAT phosphorylation in IFN-treated 
T84 cells. (a) PTPN2 was immunoprecipitated from whole cell lysates and blots were 
subsequently probed for PTPN2 to show equivalent protein in each sample. The graph 
demonstrates PTPN2 activity in response to IFN (n=4). (b) Representative Western blots show 
phosphorylated cytoplasmic (Tyr701, above) and total STAT1 (below) after IFN treatment, 
followed by densitometric analysis (n=5). (c) Western blots and densitometry showing 
phosphorylated nuclear (above) and total STAT1 (below) in IFN-treated cells (n=5). (d) 
Phosphorylated cytoplasmic (Tyr705) and total STAT3 in IFN-treated T84 cells shown by 
representative Western blots and densitometry (n=4).  Data in (b), (c) and (d) are shown as a 
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percentage of the respective control. Asterisks indicate significant differences compared to the 
respective control (*=p<0.05, **=p<0.01, ***=p<0.001). #=p<0.05; ###=p<0.001 vs. 24 h IFN 
treatment. 
 
 
 
Figure 3. PTPN2 knock-down enhances IFN-stimulated STAT1+3 phosphorylation. T84 cells 
were transfected with either non-specific siRNA or PTPN2 siRNA and treated with IFN (24h). 
(a) Representative Western blots for PTPN2 and lamin A/C followed by densitometric analysis 
(n=3). (b,c) Representative Western blots and densitometry showing STAT1+3 phosphorylation 
and expression, respectively (n=3). Figures (a) to (c) represent analyses of whole cell lysates. 
Asterisks indicate significant differences vs. the respective control (*=p<0.05, **=p<0.01, 
***=p<0.001). ###=p<0.001 vs. 24 h IFN treatment of control siRNA-transfected cells. (d) 
Representative Western blots showing PTPN2 and lamin A/C expression,  STAT1+3 expression 
and phosphorylation, in cytoplasmic and nuclear lysates (n=2). 
 
 
 
Figure 4. AMPK activation by IFNand regulation of STAT1 phosphorylation in T84 cells. (a) 
Western blots and densitometric analysis of phosphorylated and total AMPK after IFN 
treatment (n=3-7). (b) Western blots and densitometric analysis of phosphorylated and total 
AMPK after treatment with IFN and/or CC (50 M, bilaterally) (n=5). (c) Western blots and 
densitometric analysis of cytoplasmic (n=4) and (d) nuclear PTPN2 (n=3). (e) Western blot and 
densitometric analysis of cytoplasmic (n=4) and (f) nuclear (n=4) phosphorylated and total 
STAT1 in response to IFN (72h). Black dashes in (c) to (f) indicate that the gel has been 
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cropped at this position. Asterisks indicate significant differences vs. the respective control 
(*=p<0.05, **=p<0.01, ***=p<0.001). ++=p<0.01 vs. 6h IFN treatment and #=p<0.05 vs. 72h 
IFN. 
 
 
 
Figure 5. Effect of AMPK knock-down on PTPN2 distribution. (a) Confocal microscopy shows 
PTPN2 (green) in T84 cells. Nuclear staining is blue. Each panel shows a representative image for 
one experiment. Three experiments were performed with similar results for each condition. 
PTPN2 is equally distributed between the nucleus (arrow) and cytoplasm in control cells. 
Cytoplasmic PTPN2 accumulates (arrow) in response to IFN treatment (72h). Compound C had 
no effect on PTPN2 distribution vs. control cells. However, CC prevented the IFN-stimulated 
nuclear exit of PTPN2 (arrows). (b) Representative Western blots show AMPK levels in 24 h 
IFN-treated T84 cells transfected with either control or AMPK1 siRNA and densitometric 
analysis (n=4). (c) PTPN2 and lamin A/C expression (n=4). (d) Representative Western blots and 
densitometric analysis of phosphorylated and total STAT1 (n=4). Asterisks indicate significant 
differences vs. the respective control (**=p<0.01, ***=p<0.001). #=p<0.05 vs. 72h IFN 
treatment of control siRNA cells. 
 
 
 
Figure 6. FITC-dextran flux, TER and claudin-2 protein in PTPN2-deficient T84 cells. (a,b) 
Western blots showing decreased PTPN2 but not lamin A/C protein in PTPN2-deficient T84 cells 
after IFN (72 h) treatment. (a) FITC-dextran flux (n=3) and (b) TER (n=3) across T84 
monolayers transfected with either control or PTPN2 siRNA.  (c) Western blot and densitometric 
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analysis of claudin-2 expression in control or PTPN2 siRNA-transfected cells in response to 
IFN (n=3). (d) Effects of IFN on expression of the tight junction proteins claudin-4, occludin 
and ZO-1 in control or PTPN2 siRNA-transfected T84 cells (n=3). Asterisks indicate significant 
differences vs. the respective control (*=p<0.05, ***=p<0.001). #=p<0.05, ###=p<0.001 vs. 72h 
IFN treatment of control siRNA cells. 
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